Novelmed Therapeutics, Inc. was awarded a $1,599,495 Project Grant from the National Heart, Lung and Blood Institute of the Department of Health and Human Services. The grant falls under the Cardiovascular Diseases Research program (CFDA 93.837), which supports heart and vascular research. Novelmed will use the funding to develop a novel disease-modifying treatment for paroxysmal nocturnal hemoglobinuria (PNH). The company's lead drug candidate selectively inhibits the alternative pathway of...
This Project Grant award from the National Institute on Aging (part of the National Institutes of Health, CFDA# 93.866 Aging Research) provides $1,041,646 to Cenna Biosciences Inc. to support early clinical development of a novel peptide drug candidate, modified P8 (MP8), for the treatment of Alzheimer's disease. The funding will be used to conduct chemistry, manufacturing, and controls (CMC) activities to prepare for a first-in-human clinical study, hold a pre-IND meeting with the FDA, submit...
This Project Grant award from the National Institute on Aging (NIA), under CFDA 93.866 Aging Research, provides $2,432,649 to Virogenics, Inc., a biotechnology company in San Diego, California, to advance the development of their novel Alzheimer's disease drug candidate, CMS121. The funding will support two critical components: 1) a 13-week toxicology study in rats and dogs to enable longer-term clinical trials of CMS121 in human patients with mild to moderate Alzheimer's disease, and 2) the...
This $499,968 Project Grant award from the National Institute on Aging's Aging Research Federal Grant Program (CFDA 93.866) supports the development of novel, potent, and selective Kv1.3 potassium channel inhibitors as potential therapeutics for Alzheimer's disease. The awardee, Hager Biosciences, LLC, aims to further characterize and optimize lead compounds that have demonstrated efficacy in inhibiting Kv1.3 channels, which play a key role in neuroinflammatory processes associated with...
The National Institute on Aging (NIA), under the federal Aging Research grant program (CFDA 93.866), awarded a $473,216 project grant to MCM6 Therapeutics, Inc. for the period of September 25, 2024 to August 31, 2025. The grant supports the development of a high-content screening pipeline to identify small molecule therapeutics that can reduce aberrant lipid accumulation in ApoE4-expressing oligodendrocytes, a key pathological feature of Alzheimer's disease. The project aims to conduct...
This $3,357,206 Project Grant award, funded by the National Institute on Aging (CFDA 93.866 - Aging Research), supports the clinical evaluation of a novel compound, BMS-984923, for the treatment of Alzheimer's disease (AD). Allyx Therapeutics Inc. has obtained an exclusive license for the use of BMS-984923 in neurodegenerative diseases. The project seeks to develop this disease-modifying compound by targeting the underlying mechanism of synapse loss, which is tightly correlated with cognitive...
This $499,441 Project Grant awarded by the National Institute on Aging (CFDA 93.866 - Aging Research) to Acepre, LLC aims to develop a novel brain-targeted delivery system for N-acetylcysteine (TN-NAC) as a potential treatment for Alzheimer's disease (AD). The proposed research includes evaluating the toxicity and pharmacokinetic properties of TN-NAC in mice (Specific Aim 1) and testing the therapeutic efficacy of TN-NAC in a 3xTG-AD mouse model (Specific Aim 2). Successful completion of these...
The National Institutes of Health National Institute on Aging awarded Arviat Pharmaceuticals, Inc. a $1,350,180 Project Grant under the Aging Research program (CFDA 93.866) on September 30, 2021 to develop novel small-molecule inhibitors of the 12/15-lipoxygenase enzyme family. The goal is to reduce neuroinflammation and slow disease progression in Alzheimer's disease by inhibiting 12/15-LO activity. Under the award, Arviat will screen compounds from existing patent portfolios and develop...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $504,732 to Aphios Corp, a minority-owned biotechnology company, to develop a novel Alzheimer's disease therapeutic. The project aims to nanoencapsulate an anti-CCR5 drug into targeted and non-targeted nanoparticles, and evaluate their impact on brain inflammation and blood-brain barrier penetration as a potential treatment for Alzheimer's disease. In Phase I, the company will...
The National Institute on Aging awarded a $514,862 Project Grant (CFDA 93.866 - Aging Research) to Neuroindx, a for-profit, woman-owned small business, to develop an on-chip functional assay for identifying candidate microtubule-binding drugs to treat Alzheimer's Disease and related disorders (ADRDs). The grant supports the creation of an in vitro model system that can replicate key features of the neuronal microtubule microenvironment and use kinesin-based readouts to measure the ability of...
Novelmed Therapeutics, Inc. was awarded a $900,000 Project Grant from the National Institutes of Health's National Institute on Aging to develop a selective inhibitor of the alternative pathway of complement as a treatment for Neuromyelitis Optica Spectrum Disorder. Under the grant, Novelmed will conduct preclinical studies to evaluate its lead drug candidate NM5072, including in vitro and ex vivo assays to confirm the drug's mechanism of action and selective inhibition of the alternative pathway. The company will also perform toxicity studies in rhesus monkeys and tissue cross-reactivity studies using samples from NMOSD patients. If successful, these preclinical activities will enable future multi-dose clinical trials in humans. The award supports research aligned with the National Institute on Aging's Aging Research program (CFDA 93.866) to further understanding of diseases and conditions affecting older populations.